XMRV presente tejido cancer próstata, poco impacto clínico

[elipoarch]

[t]XENOTROPIC MURINE LEUKEMIA VIRUS RELATED VIRUS (XMRV) IS PRESENT IN
MALIGNANT PROSTATE TISSUE BUT DOES NOT AFFECT PATHOLOGICAL OR CLINICAL
OUTCOME[/t]
Chad Ritch, Ruslan Korets, Mireia Castillo-Martin, Josep
Domingo-Domenech, Mitchell Benson, Carlos Cordon-Cardo
The Journal of Urology
Volume 185, Issue 4, Supplement , Page e584, April 2011

INTRODUCTION AND OBJECTIVES
XMRV is a novel retrovirus that has recently been discovered in
malignant prostate tissue. It is unclear whether or not the virus has
a clinical impact on prostate cancer. The goal of the current study
was to compare XMRV infection rates in benign versus malignant
prostate tissue samples and to determine if the presence of XMRV
infection had any impact on pathological or clinical outcome in
prostate cancer.

METHODS
Radical prostatectomy (RP) samples from sixty-five (65) patients and
benign prostate samples from forty-two (42) patients (30 transurethral
resection and 12 cystoprostatectomy) were analyzed for XMRV. XMRV was
detected using both immunofluorescence (IF) staining and polymerase
chain reaction (PCR). DNA was extracted from formalin fixed paraffin
embedded tissue (FFPE) using a standard protocol (Qiagen, Valencia,
CA) and PCR was performed using sequence specific primers for XMRV.
DNA from representative PCR positive samples were sent for gene
sequencing to confirm the presence of XMRV.IF staining was performed
on paraffin embedded slides using a rabbit polyclonal anti-XMRV
antibody. Statistical analysis was then performed to determine if
there was an association between XMRV infection and PSA, stage, and
Gleason Score (GS) as well as biochemical recurrence (BCR).

RESULTS
Mean age was 62 years old and mean PSA was 7.8 ng/mL for RP patients.
Mean clinical and pathological GS was 7. Median clinical stage was T1c
and median pathological stage was T2c. Median follow-up after radical
prostatectomy was 14 months and 13/65 patients (20%) had BCR (defined
as PSA >0.2 ng/ml). Mean age for benign patients was 68 years old and
mean PSA was 3.1 ng/ml. In malignant samples, XMRV was detected via IF
in 33/65 (51%) and via PCR in 14/65 (21%). Combined, PCR and IF
detected XMRV in 11/65 (17%) of prostate cancer patients. XMRV was
detected in only 5/42 benign samples (12%) on IF and 2/42 (5%) on PCR.
One of the 42 benign samples (2%) was XMRV positive on both IF and
PCR. There was a significantly higher proportion of XMRV positive
patients in the malignant versus benign groups when stratified by
combined IF and PCR positivity (17% vs 2%, p<0.05). There was no
significant association between presence of XMRV and BCR or PSA,
Gleason Score and stage.

CONCLUSIONS
XMRV was detected in at least 17% of malignant samples and rarely
found in benign tissue. There was no significant effect of XMRV on
pathological or clinical outcome as measured by PSA, stage, GS and
BCR. Further research is necessary to determine the implications of
XMRV infection on prostate cancer.

http://www.jurology.com/article/S0022-5347(11" onclick="window.open(this.href);return false;)01618-1/fulltext